



TOTAL NUMBER OF VOTING RIGHTS AND SHARES

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 222-16 of the Règlement Général de l'Autorité des Marchés Financiers (Regulation of the French stock market authority).

Date	Total number of shares	Number of existing voting rights (GROSS)	Number of existing voting rights (NET)
05/31/2017	52, 376, 594	55, 743, 102	51, 393, 938

*Including 5.210.000 new shares in accordance with the contract of Equity line financing concluded with Kepler Cheuvreux on November 20th 2014, the second planned tranche was put in place on November 30, 2016, representing an amount raised of 3.937.400€. A shareholder holding 1.0% of the Company share capital (April 30th, 2017) would be reduced to approximately 0,88% of the capital on non-diluted basis. A total of 8, 510, 000 new shares have been issued since the beginning of the second tranche”

About Neovacs

Listed on Euronext Growth since 2010, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFN α -Kinoid, an immunotherapy being developed for the indication of lupus and dermatomyositis. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology, allergies and Type 1 diabetes. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. www.neovacs.fr

For more information on Neovacs, visit www.neovacs.fr

NEOVACS – Investor Relations

Charlène Masson

+33 (0)1 53 10 93 00

cmasson@neovacs.com

Investor Relations / Financial Communications – Life Science Advisors

Chris Maggos

chris@lifesciadvisors.com